BIOMARKERS EVOLUTION IN PATIENTS WITH SARSCOV-2 PNEUMONIA TREATED WITH BARICITINIB
4CPS-107
IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE
4CPS-105
CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HIV INFECTION WITH ANTIRETROVIRAL TREATMENT
4CPS-103
IMPROVING MEDICATION RECONCILIATION REPORTS: EVALUATION THROUGH QUALITY AUDITS
4CPS-101
BIOLOGIC AGENTS IN RHEUMATOLOGICAL DISEASES: IMPACT OF ‘TREAT TO TARGET’ IN CLINICAL PRACTICE
4CPS-099
CLINICALLY RELEVANT DRUG-DRUG INTERACTION EVENTS IN PATIENTS WITH ABIRATERONE, ENZALUTAMIDE OR APALUTAMIDE TREATMENT
4CPS-093
DRUG-INDUCED SOMNOLENCE IN FRAILTY PATIENTS ATTENDED IN AN EMERGENCY DEPARTMENT
4CPS-092
BIOLOGICAL THERAPIES FOR THE TREATMENT OF PSORIASIS: EFFECTIVENESS, SAFETY AND ECONOMIC IMPACT OF OPTIMISATION STRATEGIES
4CPS-089
RISANKIZUMAB IN REFRACTORY HIDRADENITIS SUPPURATIVA TO ANTI-TNFa A CASE REPORT
4CPS-088
INDIRECT COMPARISON OF NIVOLUMAB, PEMBROLIZUMAB AND CAMRELIZUMAB IN PATIENTS WITH UNRESECTABLE AND/OR ADVANCED SQUAMOUS CELL CARCINOMA OF ESOPHAGUS IN SECOND-LINE SETTING
4CPS-086
Inhaled sedation with halogenated agents in the Intensive Care Unit: A literature mini-review
4CPS-083
Cost-effectiveness analysis of adalimumab and its clinical alternatives in immunemediated inflammatory diseases in Spain
4CPS-082
ENVIRONMENTAL POLLUTION WITH QUINOLONES IN SPAIN
4CPS-081
SUBCUTANEOUS FUROSEMIDE INFUSION USING ELASTOMERIC INFUSION PUMPS IN A TERTIARY HOSPITAL
4CPS-080
EFFICACY AND SAFETY OF THE CONTINUOUS INFUSION OF VANCOMYCIN IN PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW
